All In Biotech

NDA 215152 · Phathom

Voquezna Triple Pak

Amoxicillin, Clarithromycin, Vonoprazan Fumarate · Oral

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Oct 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

May 3, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

918

176 Phase 3, 89 recruiting

FAERS reports

41

4 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 16, 2026.

VOQUEZNA TRIPLE PAK, is a co-packaged product containing vonoprazan, a potassium-competitive acid blocker (PCAB), amoxicillin, a penicillin class antibacterial, and clarithromycin, a macrolide antimicrobial, indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults. ( 1.1 ) VOQUEZNA DUAL PAK, is a co-packaged product containing vonoprazan, a PCAB, and amoxicillin, a penicillin class antibacterial, indicated for the treatment of H. pylori infection in adults. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK and other antibacterial drugs, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Helicobacter pylori Infection VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK are indicated for the treatment of Helicobacter pylori ( H. pylori ) infection in adults [see Clinical Studies (14) ]. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK and other antibacterial drugs, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Mechanism: Vonoprazan suppresses basal and stimulated gastric acid secretion at the secretory surface of the gastric parietal cell through inhibition of the H + , K + -ATPase enzyme system in a potassium competitive manner. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, vonoprazan has been characterized as a type of gastric proton-pump inhibitor, in that it blocks the final step of acid production. Vonoprazan does not require activation by acid. Vonoprazan may selectively concentrate in the parietal cells in both the resting and stimulated states. Vonoprazan binds to...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 3, 2022 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLetterLabelReview
1 products under this application
  • VOQUEZNA TRIPLE PAK · AMOXICILLIN 500MG; CLARITHROMYCIN 500MG; VONOPRAZAN FUMARATE EQ 20MG BASE · CAPSULE, TABLET, TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Amoxicillin" as an intervention, any sponsor and status, largest first.

All 918 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea6
  • headache6
  • dysgeusia5
  • nausea5
  • abdominal discomfort4
  • chest discomfort3
  • drug ineffective3
  • dyspepsia3
  • fatigue3
  • off label use3
  • pain3
  • palpitations3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20247
202514
202620

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Voquezna Triple Pak (Vonoprazan/Amoxicillin/Clarith)

2024 spending

$247K

Beneficiaries

311

317 claims

Per beneficiary

$793

$6.97 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$246,612

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,171 on PubMed

Sponsor: Phathom

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.